RESEARCH NEWS 2013-12-13 Research News In another victory for whole-genome technology, geneticists have identified rare variants of phospholipase D3 (PLD3) that double a person’s risk for late-onset Alzheimer’s disease (LOAD). Lead author Carlos Cruchaga of Washington University
PAPER Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, Harari O, Norton J, Budde J, Bertelsen S, Jeng AT, Cooper B, Skorupa T, Carrell D, Levitch D, Hsu S, Choi J, Ryten M, UK Brain Expression Consortium, Hardy J, Ryten M, Trabzuni D, Weale ME, Ramasamy A, Smith C, Sassi C, Bras J, Gibbs JR, Hernandez DG, Lupton MK, Powell J, Forabosco P, Ridge PG, Corcoran CD, Tschanz JT, Norton MC, Munger RG, Schmutz C, Leary M, Demirci FY, Bamne MN, Wang X, Lopez OL, Ganguli M, Medway C, Turton J, Lord J, Braae A, Barber I, Brown K, Alzheimer’s Research UK Consortium, Passmore P, Craig D, Johnston J, McGuinness B, Todd S, Heun R, Kölsch H, Kehoe PG, Hooper NM, Vardy ER, Mann DM, Pickering-Brown S, Brown K, Kalsheker N, Lowe J, Morgan K, David Smith A, Wilcock G, Warden D, Holmes C, Pastor P, Lorenzo-Betancor O, Brkanac Z, Scott E, Topol E, Morgan K, Rogaeva E, Singleton AB, Hardy J, Kamboh MI, St George-Hyslop P, Cairns N, Morris JC, Kauwe JS, Goate AM
Nature. 2014 Jan 23;505(7484):550-4. Epub 2013 Dec 11 PubMed: 24336208
CONFERENCE COVERAGE 2013-12-13 Conference Coverage Despite Eli Lilly terminating development of its BACE inhibitor LY2886721 (see Jun 2013 news story), the protease remains a popular target among pharmaceutical companies looking for the next Alzheimer's disease therapy. While BACE
Deemed universityBangalore
PAPER Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N
J Labelled Comp Radiopharm. 2014 Apr;57(4):323-31. Epub 2013 Dec 11 PubMed: 24327420